Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors.
Biomarker
Chromogranin A
Surgery
Surgical efficacy
Vasostatin-1
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
01
11
2021
accepted:
18
01
2022
pubmed:
6
2
2022
medline:
18
5
2022
entrez:
5
2
2022
Statut:
ppublish
Résumé
No single reliable biomarker is available for nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). Vasostatin-1 (VS-1), the N-terminal fragment of chromogranin A (CgA), seems to be a more accurate biomarker compared to its precursor. Primary aim was to investigate the ability of VS-1, compared to total-CgA, to assess the effectiveness of surgical resection performed for NF-PanNETs. Secondary aim was to evaluate two additional CgA-derived fragments, pancreastatin (PST) and vasostatin-2 (VS-2), as possible biomarkers for NF-PanNETs. Consecutive patients who underwent surgery for NF-PanNETs at San Raffaele Scientific Institute were included (n = 35). Plasma levels of CgA and CgA-derived fragments were measured by Enzyme-Linked ImmunoSorbent Assay (ELISA), preoperatively and postoperatively. Preoperative VS-1 was significantly higher compared to VS-1 measured on postoperative day 5 (POD5) (pre: 0.338 nM versus POD5: 0.147 nM, P < 0.001), whereas total-CgA significantly increased after surgery (pre: 1.123 nM versus POD5: 1.949 nM, P = 0.006). Overall, 24 patients showed ≥ 1 feature of tumor aggressiveness (T3-T4, nodal/distant metastases, Ki67 > 5%, microvascular/perineural invasion, necrosis). The median percentage decrease in VS-1 plasma levels was 63% (IQR 28-88%) among patients with aggressive tumors, compared to 13% (IQR 0-57%) in the remaining population (P = 0.033). No significant differences in terms of PST (P = 0.870) and VS-2 (P = 0.909) were observed between preoperative and postoperative time. VS-1 provides an early assessment of surgical efficacy in patients who undergo resection for NF-PanNETs, especially in those with aggressive neoplasms. Total-CgA, PST and VS-2 have no clinical utility in this setting.
Identifiants
pubmed: 35122631
doi: 10.1007/s40618-022-01750-5
pii: 10.1007/s40618-022-01750-5
doi:
Substances chimiques
Biomarkers, Tumor
0
Chromogranin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1209-1217Informations de copyright
© 2022. Italian Society of Endocrinology (SIE).
Références
Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342. https://doi.org/10.1001/jamaoncol.2017.0589
doi: 10.1001/jamaoncol.2017.0589
pubmed: 28448665
pmcid: 5824320
Vagefi PA, Razo O, Deshpande V et al (2007) Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 142:347–354. https://doi.org/10.1001/archsurg.142.4.347
doi: 10.1001/archsurg.142.4.347
pubmed: 17438169
pmcid: 3979851
Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103:153–371. https://doi.org/10.1159/000443171
doi: 10.1159/000443171
pubmed: 26742109
Genç CG, Falconi M, Partelli S et al (2018) Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol 25:2467–2474. https://doi.org/10.1245/s10434-018-6518-2
doi: 10.1245/s10434-018-6518-2
pubmed: 29789972
pmcid: 6028862
Hashim YM, Trinkaus KM, Linehan DC et al (2014) Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg 259:197–203. https://doi.org/10.1097/SLA.0000000000000348
doi: 10.1097/SLA.0000000000000348
pubmed: 24253141
Partelli S, Javed AA, Andreasi V et al (2018) The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. Eur J Surg Oncol 44:778–783. https://doi.org/10.1016/j.ejso.2018.03.005
doi: 10.1016/j.ejso.2018.03.005
pubmed: 29610023
Zaidi MY, Lopez-Aguiar AG, Switchenko JM et al (2019) A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006 patients. Ann Surg 270:422–433. https://doi.org/10.1097/SLA.0000000000003461
doi: 10.1097/SLA.0000000000003461
pubmed: 31283562
Howe JR, Merchant NB, Conrad C et al (2020) The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49:1–33. https://doi.org/10.1097/MPA.0000000000001454
doi: 10.1097/MPA.0000000000001454
pubmed: 31856076
pmcid: 7029300
Jilesen APJ, Busch ORC, van Gulik TM et al (2014) Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors–diagnostic accuracy: NF-pNET and low tumor burden. Dig Surg 31:407–414. https://doi.org/10.1159/000370007
doi: 10.1159/000370007
pubmed: 25572908
Partelli S, Andreasi V, Muffatti F et al (2020) Circulating neuroendocrine gene transcripts (NETest): a postoperative strategy for early identification of the efficacy of radical surgery for pancreatic neuroendocrine tumors. Ann Surg Oncol 27:3928–3936. https://doi.org/10.1245/s10434-020-08425-6
doi: 10.1245/s10434-020-08425-6
pubmed: 32253675
Marotta V, Zatelli MC, Sciammarella C et al (2018) Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer 25:R11–R29. https://doi.org/10.1530/ERC-17-0269
doi: 10.1530/ERC-17-0269
pubmed: 29066503
Oberg K (2011) Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 18(Suppl 1):S17-25. https://doi.org/10.1530/ERC-10-0280
doi: 10.1530/ERC-10-0280
pubmed: 22005113
Andreasi V, Partelli S, Muffatti F et al (2021) Update on gastroenteropancreatic neuroendocrine tumors. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 53:171–182. https://doi.org/10.1016/j.dld.2020.08.031
doi: 10.1016/j.dld.2020.08.031
Giusti M, Sidoti M, Augeri C et al (2004) Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 150:299–303. https://doi.org/10.1530/eje.0.1500299
doi: 10.1530/eje.0.1500299
pubmed: 15012614
Pregun I, Herszenyi L, Juhasz M et al (2011) Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 84:22–28. https://doi.org/10.1159/000321535
doi: 10.1159/000321535
pubmed: 21304238
Dam G, Grønbæk H, Sorbye H et al (2020) Prospective study of chromogranin a as a predictor of progression in patients with pancreatic, small-intestinal, and unknown primary neuroendocrine tumors. Neuroendocrinology 110:217–224. https://doi.org/10.1159/000503833
doi: 10.1159/000503833
pubmed: 31578011
Brehm Hoej L, Parkner T, Soendersoe Knudsen C, Grønbaek H (2014) A comparison of three chromogranin A assays in patients with neuroendocrine tumours. J Gastrointestin Liver Dis 23:419–424. https://doi.org/10.15403/jgld.2014.1121.234.3ca
Baekdal J, Krogh J, Klose M et al (2020) Limited diagnostic utility of chromogranin a measurements in workup of neuroendocrine tumors. Diagnostics (Basel, Switzerland) 10:881. https://doi.org/10.3390/diagnostics10110881
doi: 10.3390/diagnostics10110881
Giovinazzo F, Schimmack S, Svejda B et al (2013) Chromogranin A and its fragments as regulators of small intestinal neuroendocrine neoplasm proliferation. PLoS One 8:e81111. https://doi.org/10.1371/journal.pone.0081111
doi: 10.1371/journal.pone.0081111
pubmed: 24260544
pmcid: 3834250
Corsello A, Di Filippo L, Massironi S et al (2018) Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. PLoS ONE 13:e0196858. https://doi.org/10.1371/journal.pone.0196858
doi: 10.1371/journal.pone.0196858
pubmed: 29723285
pmcid: 5933774
Sherman SK, Maxwell JE, O’Dorisio MS et al (2014) Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol 21:2971–2980. https://doi.org/10.1245/s10434-014-3728-0
doi: 10.1245/s10434-014-3728-0
pubmed: 24752611
pmcid: 4125469
Andreasi V, Partelli S, Manzoni M et al (2019) Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). Pancreatology 19:57–63. https://doi.org/10.1016/j.pan.2018.11.005
doi: 10.1016/j.pan.2018.11.005
pubmed: 30470614
Bossuyt PM, Reitsma JB, Bruns DE et al (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 351:h5527. https://doi.org/10.1136/bmj.h5527
doi: 10.1136/bmj.h5527
pubmed: 26511519
pmcid: 4623764
Crippa L, Bianco M, Colombo B et al (2013) A new chromogranin A-dependent angiogenic switch activated by thrombin. Blood 121:392–402. https://doi.org/10.1182/blood-2012-05-430314
doi: 10.1182/blood-2012-05-430314
pubmed: 23190532
pmcid: 3544118
Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401. https://doi.org/10.1007/s00428-006-0250-1
doi: 10.1007/s00428-006-0250-1
pubmed: 16967267
pmcid: 1888719
Lloyd RV, Osamura RY, Kloppel G, Rosai J (2017) WHO Classification of Tumours of Endocrine Organs, 4th edn. IARC Press, Lyon
Oberg K, Modlin IM, De Herder W et al (2015) Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol 16:e435–e446. https://doi.org/10.1016/S1470-2045(15)00186-2
doi: 10.1016/S1470-2045(15)00186-2
pubmed: 26370353
pmcid: 5023063
Tran CG, Sherman SK, Scott AT et al (2021) It is time to rethink biomarkers for surveillance of small bowel neuroendocrine tumors. Ann Surg Oncol 28:732–741. https://doi.org/10.1245/s10434-020-08784-0
doi: 10.1245/s10434-020-08784-0
pubmed: 32656719
Woltering EA, Voros BA, Beyer DT et al (2019) Plasma pancreastatin predicts the outcome of surgical cytoreduction in neuroendocrine tumors of the small bowel. Pancreas 48:356–362. https://doi.org/10.1097/MPA.0000000000001263
doi: 10.1097/MPA.0000000000001263
pubmed: 30768573
Pulvirenti A, Rao D, Mcintyre CA et al (2019) Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford) 21:612–618. https://doi.org/10.1016/j.hpb.2018.09.016
doi: 10.1016/j.hpb.2018.09.016
Tseng C-M, Cheng T-Y, Chen T-B et al (2018) Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors. Oncol Lett 15:8951–8958. https://doi.org/10.3892/ol.2018.8472
doi: 10.3892/ol.2018.8472
pubmed: 29805630
pmcid: 5958764
Qiu W, Christakis I, Silva A et al (2016) Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf) 85:400–407. https://doi.org/10.1111/cen.13119
doi: 10.1111/cen.13119
Strosberg D, Schneider EB, Onesti J et al (2018) Prognostic impact of serum pancreastatin following chemoembolization for neuroendocrine tumors. Ann Surg Oncol 25:3613–3620. https://doi.org/10.1245/s10434-018-6741-x
doi: 10.1245/s10434-018-6741-x
pubmed: 30182331
Woltering EA, Beyer DT, Thiagarajan R et al (2016) Elevated plasma pancreastatin, but not chromogranin a, predicts survival in neuroendocrine tumors of the duodenum. J Am Coll Surg 222:534–542. https://doi.org/10.1016/j.jamcollsurg.2015.12.014
doi: 10.1016/j.jamcollsurg.2015.12.014
pubmed: 26827125
Pavel M, Jann H, Prasad V et al (2017) NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. Neuroendocrinology 104:170–182. https://doi.org/10.1159/000446025
doi: 10.1159/000446025
pubmed: 27078712
Laskaratos F-M, Liu M, Malczewska A et al (2020) Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection. Endocrine 69:430–440. https://doi.org/10.1007/s12020-020-02289-2
doi: 10.1007/s12020-020-02289-2
pubmed: 32291735
pmcid: 7392928
Modlin IM, Kidd M, Frilling A et al (2021) Molecular genomic assessment using a blood-based mRNA signature (NETest) is cost effective and predicts neuroendocrine tumor recurrence with 94% accuracy. Ann Surg 274:481–490. https://doi.org/10.1097/SLA.0000000000005026
doi: 10.1097/SLA.0000000000005026
pubmed: 34183517
Modlin IM, Kidd M, Oberg K et al (2021) Early identification of residual disease after neuroendocrine tumor resection using a liquid biopsy multigenomic mRNA signature (NETest). Ann Surg Oncol 28:7506–7517. https://doi.org/10.1245/s10434-021-10021-1
doi: 10.1245/s10434-021-10021-1
pubmed: 34008138
Oberg K, Krenning E, Sundin A et al (2016) A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 5:174–187. https://doi.org/10.1530/EC-16-0043
doi: 10.1530/EC-16-0043
pubmed: 27582247
pmcid: 5045519